ArticleRespiratory research2026
Differences in microRNA levels across metabo-endotypes reveal novel insights into asthma heterogeneity.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
rationaleWe previously validated five clinically distinct asthma metabo-endotypes (mechanistically derived asthma subgroups). We hypothesize that metabo-endotype membership may be partially driven by differences in serum microRNA profiles and their influence on metabolite levels.
objectivesTo determine whether serum miRNA levels can help understand the underlying drivers of metabolic dysregulation across metabo-endotypes.
methodWe compared expression levels of serum microRNAs across 1121 children grouped into five asthma metabo-endotypes using ANCOVA. A LASSO model was leveraged to determine the most important miRNAs for discriminating metabo-endotype membership. Finally, multiple linear regression models and two-sample t-tests were employed to determine whether serum microRNA ~ plasma metabolite relationships differed between individuals within different metabo-endotypes. MEASUREMENTS AND MAIN
resultsOf 317 serum miRNAs, 132 (41.6%) demonstrated significantly different expression across metabo-endotypes (FDR < 0.05), with miR-143-3p showing the greatest variation (FDR p = 5.7 × 10− 19). Most differences were driven by metabo-endotypes 2 and 3, the most and least severe. Enrichment analysis of microRNAs’ predicted target genes revealed critical asthma pathways, including Th17 and Th1/Th2 cell differentiation. A model based on 17 miRNAs was able to discriminate membership of metabo-endotype 2 versus 3 (AUC:81%, CI: 73%-88%). There was some evidence that relationships between specific miRNAs and metabolites differed between individuals in metabo-endotypes 2 and 3, which may suggest differential posttranscriptional regulation of pathways including eicosanoid and arginine metabolism.
conclusionsThe results provide some evidence to suggest differential miRNA regulated gene expression between biologically and clinically distinct asthma metabo-endotypes, with a potentially important role for miR-143-3p. Understanding these relationships may uncover novel therapeutic targets and guide more personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.